Abstract
The anti-CD20 monoclonal antibody ocrelizumab reduces disability progression in primary progressive multiple sclerosis. CD20 is a prototypical B cell marker, however subpopulations of CD4+ and CD8+ T cells in peripheral blood and cerebrospinal fluid (CSF) also express low levels of CD20 (CD20dim). Therefore, direct targeting and depletion of these CD20dim T-cell-subpopulations may contribute to the therapeutic effect of ocrelizumab. The aim of this observational cohort study was to compare CD20+ B cell and CD20dim T cell distributions between peripheral blood and CSF of ocrelizumab-treated or untreated people with primary progressive multiple sclerosis. Ocrelizumab treatment was associated with depletion of circulating B cells and CD20dim CD4+ and CD20dim CD8+ T cells (P < 0.0001, P = 0.0016, and P = 0.0008, respectively), but in CSF only with lower proportions of B cells and CD20dim memory CD4+ T cells (P < 0.0001 and P = 0.0043, respectively). The proportional prevalence of CSF CD20dim memory CD8+ T cells was not significantly reduced (P = 0.1333). Only in CSF, the proportions of CD20dim cells within CD4+ and not CD8+ T cells positive for CCR5, CCR6 and CXCR3 were reduced in ocrelizumab-treated participants. The proportion of CD20dim CD4+ T cells and abundance of CD4+ relative to CD8+ T cells in CSF correlated positively with age (R = 0.6799, P = 0.0150) and Age Related Multiple Sclerosis Severity Score (R = 0.8087, P = 0.0014), respectively. We conclude that, in contrast to CSF CD20dim CD8+ T cells, B cells and CD20dim CD4+ T cells are reduced in CSF of people with primary progressive multiple sclerosis with an ocrelizumab-associated depletion of circulating B cells and CD20dim T cells. Therefore, these cells are likely to contribute to the therapeutic effects of ocrelizumab in people with primary progressive multiple sclerosis.
Funding Information
  • Dutch Research Council (09150171910036)
  • stichting beterketen
  • Nationaal MS Fonds

This publication has 67 references indexed in Scilit: